Chronic Myeloproliferative Disorders Terminated Phase 2 Trials for Azacitidine (DB00928)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00381693Azacitidine in Treating Patients With MyelofibrosisTreatment